Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : A Real American President: Donald Trump -- Ignore unavailable to you. Want to Upgrade?

To: kckip who wrote (250952)	12/20/2020 4:01:43 PM
From: E_K_S	3 Recommendations Recommended By CF Rebel Honey_Bee kckip Read Replies (1) \| Respond to of 455940

I somewhat agree but side effect s/d be expected and based on the total doses (272K) vs those affected (3,259) or 1.15%. Not sure if 1.5% is deemed outside the normal range. It appears small to me. The current vaccine trials are/were not long term trials (>2 years). Therefore no data on long term coverage especially w/ 2nd-3rd generation strains (variants). It may be a vaccine that needs to be updated each year similar to the current flu shot to provide best protection. ------------------------------------------------------ FWIW, heard a successful Hedge Fund operator that this Sector of Bio Gene Development combined w/ AI & Big Data, is here to stay and it is only a matter of time that we see custom vaccines designed for everybody. Labs do RNA splicing using Crisper Technology. AI and Big Data software (processed on virtual super computers in the cloud) can design the optimal individual vaccine w/i minutes.